TARCEVA for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 64 adverse event reports in the FDA FAERS database where TARCEVA was used for Non-small cell lung cancer.
Most Reported Side Effects for TARCEVA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 274 | 44.0% | 274 | 12 |
| Rash | 81 | 13.0% | 24 | 18 |
| Diarrhoea | 65 | 10.4% | 20 | 24 |
| Incorrect dose administered | 48 | 7.7% | 29 | 4 |
| Nausea | 31 | 5.0% | 9 | 11 |
| Malignant neoplasm progression | 29 | 4.7% | 19 | 5 |
| Vomiting | 25 | 4.0% | 4 | 13 |
| Disease progression | 21 | 3.4% | 9 | 3 |
| Off label use | 16 | 2.6% | 9 | 2 |
| Decreased appetite | 15 | 2.4% | 4 | 7 |
| Dehydration | 15 | 2.4% | 1 | 12 |
| Dry skin | 15 | 2.4% | 4 | 2 |
| Alopecia | 14 | 2.3% | 1 | 1 |
| Fatigue | 13 | 2.1% | 2 | 5 |
| Dyspnoea | 12 | 1.9% | 2 | 8 |
Other Indications for TARCEVA
Lung neoplasm malignant (316)
Product used for unknown indication (98)
Lung carcinoma cell type unspecified stage 0 (24)
Lung adenocarcinoma (20)
Pancreatic carcinoma (19)
Bronchial carcinoma (15)
Neoplasm malignant (12)
Tracheal cancer (7)
Lung cancer metastatic (5)
Lung carcinoma cell type unspecified stage iv (5)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)